Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trialHuman Clinical Trial · 2026
2Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial2024 · 57 citations
3Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18–49 Years of Age2025 · 1 citations
4Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18–49 Years of Age2025
5Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases2024 · 37 citations
6Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adultsClinical Trial · 2026 · 5 citations
7Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial2025 · 7 citations
8Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial2024 · 3 citations
9Gene therapy for hypertrophic cardiomyopathy: From feasibility to a fieldwide frameworkMed · 2026
10Rewriting the sarcomere: Gene therapy approaches for hypertrophic cardiomyopathy from bench to bedsideMed · 2026

More from Chinese Academy of Medical Sciences & Peking Union Medical College